Consensus meeting date and panel members:
Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia
Version of Record online: 2 MAY 2006
APLAR Journal of Rheumatology
Volume 9, Issue 1, pages 24–36, April 2006
How to Cite
LAU, E. M. C., SAMBROOK, P., SEEMAN, E., LEONG, K. H., LEUNG, P. C. and DELMAS, P. (2006), Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia. APLAR Journal of Rheumatology, 9: 24–36. doi: 10.1111/j.1479-8077.2006.00161.x
18 January 2004, Hong Kong
S. Bavonratanavech (Thailand), H. Choi (South Korea), P. Delmas (France), R. Handa (India), E.M.C. Lau (China), J.K. Lee (Malaysia), KH Leong (Singapore), P.C. Leung (China), X.W. Meng (China), H. Morii (Japan), P. Sambrook (Australia), E. Seeman (Australia), S. Siribaddana (Sri Lanka), T Torralba (Philippines)
Note: These guidelines are based mainly on the consensus discussion held in Hong Kong in January 2004. Some key research findings published after that date were added by members of the writing group.
- Issue online: 2 MAY 2006
- Version of Record online: 2 MAY 2006
- dual X-ray densitometry;
- strontium ranleate
According to the World Health Organization criteria, osteoporosis can be defined as a bone mineral density of −2.5 or more. Dual X-ray densitometry is the recognised method for diagnosing osteoporosis. Drugs which have been shown to be efficacious in treating osteoporosis include alendronate, residronate, ibandronate, raloxifene, teriparitide and strontium ranleate. Patients with established osteoporosis should be treated. Primary prevention of osteoporosis is important at the community level.